Table 3.
Univariate and multivariate logistic regression for clinical predictors of pulmonary hypertension
| Univariate | Multivariable | |||||
|---|---|---|---|---|---|---|
| Characteristic | OR | 95% CI | p-value | OR | 95% CI | p-value |
| Age | 1.08 | 1.01–1.16 | 0.027 | |||
| Female gender | 0.35 | 0.12–1.02 | 0.055 | 0.21 | 0.05–0.90 | 0.035 |
| Time from MF diagnosis to ECHO | 1.00 | 1.00–1.00 | 0.317 | |||
| MF type | ||||||
| Primary MF | 1.00 | 1.00–1.00 | . | |||
| Post-ET MF | 1.43 | 0.45–4.52 | 0.544 | |||
| Post-PV MF | 0.60 | 0.16–2.28 | 0.453 | |||
| JAK2 mutation present | 1.02 | 0.40–2.62 | 0.965 | |||
| WHO grading MF | ||||||
| MF-1 | 1.00 | 1.00–1.00 | . | |||
| MF-2 | 1.31 | 0.25–6.79 | 0.751 | |||
| MF-3 | 0.96 | 0.18–5.24 | 0.962 | |||
| DIPSS | ||||||
| Low and intermediate risk | 1.02 | 0.36–2.91 | 0.972 | |||
| High risk | 1.80 | 0.48–6.80 | 0.386 | |||
| Active therapy | 0.94 | 0.36–2.47 | 0.902 | |||
| Hypertension | 3.57 | 1.13–11.29 | 0.030 | |||
| Hyperlipidemia | 3.21 | 1.20–8.58 | 0.020 | |||
| Coronary artery disease | 4.84 | 1.53–15.36 | 0.007 | |||
| Atrial fibrillation | 1.24 | 0.14–11.22 | 0.847 | |||
| Hypothyroidism | 1.83 | 0.66–5.02 | 0.243 | |||
| Diabetes mellitus | 0.54 | 0.07–4.39 | 0.561 | |||
| COPD | 1.24 | 0.14–11.22 | 0.847 | |||
| Dyspnea | 4.56 | 1.54–13.47 | 0.006 | |||
| Splenomegaly | 2.47 | 0.78–7.85 | 0.124 | |||
| Hepatomegaly | 2.35 | 0.80–6.87 | 0.120 | |||
| ECOG Performance Status |
||||||
| 0 to 1 | 1.60 | 0.57–4.51 | 0.374 | |||
| 2 to 4 | 0.80 | 0.086–7.39 | 0.844 | |||
| WBC | 1.00 | 0.99–1.02 | 0.623 | |||
| Hemoglobin | 0.81 | 0.61–1.07 | 0.134 | |||
| Hematocrit | 0.91 | 0.83–1.00 | 0.048 | |||
| Platelets | 1.00 | 0.99–1.00 | 0.200 | |||
| BNP * ^ | 1.87 | 1.16–3.02 | 0.010 | |||
| NT-proBNP ^ | 1.07 | 1.02–1.12 | 0.008 | 1.07 | 1.02–1.12 | 0.006 |
*
BNP was not used in the multivariate model to avoid collinearity with NT-proBNP
^
Value were divided by 100
PH, pulmonary hypertension; MF, myelofibrosis; ECHO, echocardiogram; Post-ET, myelofibrosis post-essential thrombocytopenia; Post-PV, myelofibrosis post-polycythemia vera; WHO, World Health Organization; DIPSS, dynamic international prognostic scoring system; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell count; BNP, brain natriuretic peptide; NT-ProBNP, N-terminal-pro hormone brain natriuretic peptide